Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quanterix Corporation (NASDAQ: QTRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑supported context to help interpret them. As a life sciences and testing laboratories company focused on ultra-sensitive biomarker detection and spatial biology, Quanterix uses its SEC reports to describe its financial performance, corporate transactions, and governance decisions.
Key documents available here include Form 10‑K annual reports and Form 10‑Q quarterly reports, which outline revenue from product sales, service and other revenue, collaboration and license revenue, and grant revenue. These filings also discuss cost of goods sold, research and development expenses, selling, general and administrative expenses, and the use of non‑GAAP measures such as adjusted EBITDA, adjusted gross margin, and adjusted cash usage. AI summaries can highlight how these metrics relate to Quanterix’s Simoa platforms, Accelerator Laboratory services, and the integration of Akoya Biosciences.
Frequent Form 8‑K current reports document material events. Recent examples include announcements of quarterly financial results, the completion and pro forma impact of the Akoya acquisition, shareholder votes on declassifying the Board and eliminating supermajority voting requirements, and changes in Board composition. Our tools surface the main points of each 8‑K so readers can quickly understand what changed and why it matters for QTRX.
Investors can also review proxy statements referenced in the filings for details on director elections, executive compensation proposals, and governance changes, as well as any Form 4 insider transaction reports that may be filed separately. Real‑time updates from EDGAR ensure that new filings appear promptly, while AI‑generated explanations help translate technical accounting and legal language into more accessible summaries.
Use this page to explore Quanterix’s historical and current SEC filings, compare reporting periods, and understand how financial results, acquisitions, and governance actions are reflected in official disclosures.
Quanterix Corporation’s Chief Financial Officer, Sriram Vandana, reported a routine tax-related share withholding. On February 4, 2026, 4,395 shares of common stock were withheld by Quanterix to cover tax obligations from the vesting of 12,678 restricted stock units (RSUs).
After this transaction, the CFO beneficially owned 81,618 shares of Quanterix common stock, which includes 55,884 RSUs. This filing reflects a non-open-market transaction coded "F," indicating shares retained for taxes rather than a discretionary sale into the market.
Quanterix CorpEverett CunninghamJanuary 19, 2026813,750 performance-based restricted stock units (RSUs)1,070,000 time-based RSUs
The performance-based RSUs vest only if the volume-weighted average price of Quanterix stock meets specified thresholds within a four-year period, as outlined in his January 8, 2026 employment agreement. The time-based RSUs vest in four equal annual installments on January 19, 2027, 2028, 2029, and 20301,883,750 derivative securities$0
Quanterix Corp filed an initial ownership report for Everett Cunningham, who serves as President, CEO, and a director of the company. This Form 3 indicates that, as of the event date of 01/19/2026, he reports no securities beneficially owned in Quanterix. Both the non-derivative and derivative security tables show no holdings, and the remarks section explicitly states that no securities are beneficially owned.
Quanterix Corporation’s Chief Financial Officer, Sriram Vandana, reported an automatic share withholding related to equity compensation. On 01/15/2026, 274 shares of Quanterix common stock were withheld by the company at a price of $7.95 per share solely to cover tax obligations upon the vesting of 777 restricted stock units (RSUs).
Following this tax withholding, Vandana beneficially owned 86,013 shares of Quanterix common stock, which includes 68,562 RSUs. The company’s year-end reconciliation identified a variance of 310 shares, and the corrected balance is reflected in the reported holdings.
Quanterix Corp President & CEO Masoud Toloue reported a routine tax-related share withholding in company stock. On 01/15/2026, 1,817 shares of Quanterix common stock were withheld by the company at a price of $7.95 per share to cover tax obligations arising from the vesting of 3,722 restricted stock units (RSUs). After this transaction, Toloue beneficially owned 507,310 shares of common stock, which the filing notes include 206,398 RSUs. A year-end reconciliation by Quanterix identified a variance of 681 shares, and the corrected ownership balance is reflected in this filing.
Quanterix Corp director Paul M. Meister reported a stock-based board fee grant. On 01/02/2026, he acquired 3,974 shares of Quanterix common stock at a stated price of $0.00 per share as stock granted in lieu of cash fees for service on the company's Board of Directors and its committees for the third and fourth quarter of 2025. After this grant, he beneficially owned 313,253 shares of Quanterix common stock held directly.
Quanterix Corporation director Ivana Magovcevic-Liebisch received an equity grant of 23,372 restricted stock units (RSUs) of common stock on January 2, 2026. The RSUs were granted at a price of $0.00 per unit under the company’s Amended and Restated Non-Employee Director Compensation Policy.
The RSUs vest as to 100% of the shares on January 2, 2027, meaning they convert into common shares on that date if vesting conditions are met. Following this grant, she beneficially owns 43,607 RSUs, each representing the right to receive one share of Quanterix common stock.
Quanterix Corporation director Elliott Jeffrey Thomas reported a stock-based award from the company. On January 2, 2026, he received 23,372 shares of Quanterix common stock in the form of restricted stock units at a price of $0.00 per share under the Amended and Restated Non-Employee Director Compensation Policy.
These restricted stock units vest as to 100% of the shares on January 2, 2027, and each unit represents the right to receive one share of common stock. Following this grant, Thomas beneficially owned a total of 42,792 shares of Quanterix common stock, which includes 31,402 restricted stock units.
Quanterix Corporation announced a leadership change, with President and CEO Masoud Toloue, Ph.D., entering a separation agreement under which his employment and Board service end effective January 19, 2026. He will receive severance consistent with a termination without cause, accelerated vesting of equity that would have vested by April 30, 2026, and extended time to exercise vested stock options through December 31, 2026.
The Board appointed Everett Cunningham as President and CEO, and as a Class II director with a term ending at the 2028 annual meeting, effective January 19, 2026. His employment agreement provides a $750,000 annual base salary, an annual bonus target up to 100% of salary, and a $600,000 sign-on cash payment subject to repayment conditions. He also received time-based RSUs covering 1,070,000 shares and performance-based RSUs covering 813,750 shares, which vest over time and upon stock price hurdles at $10, $15, and $20 per share or in connection with certain change-in-control events. The company also furnished a press release that includes expectations for select full-year 2025 financial results.
Quanterix Corporation director David R. Walt received 1,215 shares of common stock on 01/02/2026, reported at a price of $0.00 per share. According to the filing, this stock was granted in lieu of cash fees for his service on the company’s Board of Directors and its committees for the fourth quarter of 2025.
After this grant, Walt beneficially owned 1,872,890 shares of Quanterix common stock, held directly. The transaction was reported on a Form 4 as an acquisition of non-derivative securities.